Research Alerts — Active Clinical Trials

Tracking active clinical trials for key research peptides from ClinicalTrials.gov — semaglutide, tirzepatide, retatrutide, BPC-157, and more.

Tracking key clinical trials for peptides covered in the wiki. Data sourced from ClinicalTrials.gov. Last reviewed March 2026.

Semaglutide

NCT: NCT03574597
Phase: 3 (completed, long-term follow-up ongoing)
Sponsor: Novo Nordisk
Key Result: 20% reduction in MACE (major adverse cardiovascular events) in overweight/obese adults without diabetes
Status: Published in NEJM; long-term extension data continuing

NCT: NCT05929066 (TRIUMPH-1)
Phase: 3
Sponsor: Eli Lilly
Mechanism: Triple GIP/GLP-1/glucagon receptor agonist
Phase 2 Result: Up to 24.2% weight loss at 48 weeks (highest reported for any anti-obesity agent)
Status: Phase 3 enrollment ongoing; multiple TRIUMPH trials registered

NCT: NCT05093634
Phase: 3
Sponsor: Rhythm Pharmaceuticals
Mechanism: MC4 receptor agonist for genetic obesity (POMC, LEPR, PCSK1 deficiency)
Status: FDA-approved for rare genetic obesity (Imcivree); EMANATE studying expanded populations

Registered trials: Limited — BPC-157 remains primarily a preclinical compound
NCT04881981: A registered study examining BPC-157 in inflammatory bowel disease (status uncertain)
Evidence base: 100+ preclinical studies across multiple tissue types, but no completed Phase 2/3 human RCTs published as of March 2026
Note: The gap between preclinical promise and clinical trial registration remains one of the most discussed topics in peptide research

NCT: NCT05189210
Phase: 2
Sponsor: GemVax & KAEL
Mechanism: Telomerase-derived peptide vaccine; anti-neuroinflammatory
Target: Moderate Alzheimer's disease
Key Result: Phase 2 Korean study reported cognitive improvements (MMSE, ADAS-cog) vs placebo at 24 weeks
Status: Results published; multinational Phase 3 planning

NCT: NCT05803421
Phase: 3
Sponsor: Eli Lilly
Mechanism: Oral small-molecule GLP-1 receptor agonist (not a peptide, but relevant to the GLP-1 landscape)
Phase 2 Result: Up to 14.7% weight loss at 36 weeks
Status: Phase 3 enrollment active

This page is updated monthly. For each trial:

NCT numbers link directly to ClinicalTrials.gov for full protocol details
Phase indicates the trial stage (Phase 2 = efficacy signal; Phase 3 = confirmatory)
Key Results are from published papers or conference presentations only — no leaked or preliminary data

Want a peptide's trials tracked here? Check if it has registered trials on ClinicalTrials.gov and let us know.